The Quantellect read.As of Nov 19, 2026, 9 active firms cover Pacira BioSciences, Inc: 1 rate it Buy or better, 8 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $25.00 to $36.50, a moderate spread. The average target of $33.33 sits 9% below the current $36.48. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.73 next quarter toward $3.51 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Neutral
Strong Buy00%
Buy111%
Neutral889%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$33.33
-8.6% downside
Average target across 9 active firms as of Nov 19, 2026 vs $36.48 current
Highest Target$36.50
Average Target$33.33
Lowest Target$25.00
Detailed analyst forecasts for PCRX
Showing 1–8 of 8 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 1 of 9 active firms rate PCRX a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PCRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.73
Range $0.65 – $0.89 · 4 analysts · +22% YoY
Next period, 4 analysts expect Pacira BioSciences, Inc. to earn $0.73 a share (range $0.65 – $0.89), versus $0.60 a year earlier. Full-year consensus is $3.04, growing to $3.51 the year after.
REVENUE · NEXT QUARTER
$181.5M
Range $175.7M – $185.1M · 4 analysts · +2% YoY
Revenue is expected to reach $181.5M (range $175.7M – $185.1M), +2.3% year-over-year. Full-year consensus is $741.0M, rising to $789.2M next year.
Top analysts covering Pacira BioSciences, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PCRX.
#1
Serge Belanger
Needham · Rank #129
Neutral
No targeton PCRX
Overall win rate
46%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #217
Buy
$65.00+78.2% to target
Overall win rate
54%
+ Follow
#3
Balaji Prasad
Barclays · Rank #226
Buy
$24.00-34.2% to target
Overall win rate
45%
+ Follow
#4
DM
Douglas Miehm
RBC Capital · Rank #263
Neutral
$36.50+0.1% to target
Overall win rate
43%
+ Follow
#5
Gregory Renza
RBC Capital · Rank #277
Neutral
$18.00-50.7% to target
Overall win rate
35%
+ Follow
PCRX stock forecast FAQ
What is PCRX's average 12-month price target?+
The 9 active firms with a live target average $33.33 for Pacira BioSciences, Inc. over the next 12 months, ranging from a $36.50 high to a $25.00 low, as of Nov 19, 2026.
Is PCRX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 9 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 8 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PCRX?+
The Street-high target is $36.50 (Truist Securities), and the Street-low is $25.00 (Barclays). The average of all 9 active-firm targets is $33.33.
How many active Wall Street firms cover PCRX?+
9 active firms have a recognized rating on Pacira BioSciences, Inc. as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PCRX?+
Among analysts who currently cover PCRX, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #129). Their current call is Neutral.
What is Pacira BioSciences, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.73 per share (range $0.65 – $0.89) across 4 analysts. Full-year EPS is projected at $3.04, rising to $3.51 the following year.
How much revenue is Pacira BioSciences, Inc. expected to report next quarter?+
Consensus revenue is $181.5M (range $175.7M – $185.1M). Full-year revenue is projected at $741.0M, growing to $789.2M next year.
Have analysts been upgrading or downgrading PCRX lately?+
As of Nov 19, 2026, 1 of 9 active firms rate PCRX a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PCRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.